摘要
目的:评价氨磺必利与利培酮治疗精神分裂症的疗效和安全性。方法:检索氨磺必利与利培酮治疗精神分裂症相关的随机对照研究文献,纳入合格文献进行Meta分析。结果:共纳入10篇文献,802例患者纳入分析。Meta分析结果显示:两组治疗后临床有效率、阳性和阴性症状量表(PANSS)评分及治疗中出现的症状量表(TESS)评分比较,差异无统计学意义(P>0.05);药品不良反应发生率:内分泌功能、锥体外系症状、体重增加及心血管系统不良反应比较,氨磺必利少于利培酮(P<0.05);恶心、呕吐发生率氨磺必利多于利培酮(P<0.05);两组失眠、头痛、头晕及其他不良反应比较,差异无统计学意义(P>0.05)。讨论:现有文献分析结果表明,氨磺必利治疗精神分裂症安全、有效。
Objective： To evaluate the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia. Methods： The RCTs literatures on amisulpride and risperidone in the treatment of schizophrenia were retrieved and screened,and the qualified ones were analyzed by meta-analysis. Results： A total of 10 literatures were included involving 802 patients. Meta-analysis results showed that the difference between the two groups after the treatment was not statistically significant by comparing the clinical efficiency,PANSS score and TESS score. About the incidence of adverse reactions,amisulpride was better than risperidone in the endocrine function,extrapyramidal symptoms,weight gain and cardiovascular system. The incidence of nausea and vomiting of amisulpride was more than that of risperidone. There was no statistical significance in insomnia,headache,dizziness and the others. Conclusion： Existing literature analysis shows that amisulpride is safe and effective in the treatment of schizophrenia.
出处
《中国药师》
CAS
2015年第2期280-283,共4页
China Pharmacist
